When CeD patients were classified into two categories according to GFD compliance (Fig. 4), those who were compliant had significantly lower levels of anti-gliadin and anti-transglutaminase IgA CeD biomarkers than non-compliant patients (Fig. 4B, D and E). This evidence concerns the gene CD79A and cranioectodermal dysplasia.